within Pharmacolibrary.Drugs.ATC.L;

model L01XX53
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.999999999999999e-05,
    adminDuration  = 600,
    adminMass      = 72 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.112,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.133,
    k12             = 26.5,
    k21             = 26.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX53</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vosaroxin is an experimental anticancer quinolone derivative acting as a topoisomerase II inhibitor. It was being developed for the treatment of acute myeloid leukemia (AML) but is not approved for use; development was discontinued after phase III trials did not meet efficacy endpoints.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with relapsed or refractory acute myeloid leukemia after intravenous administration.</p><h4>References</h4><ol><li><p>Nijenhuis, CM, et al., &amp; Beijnen, JH (2017). Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. <i>Investigational new drugs</i> 35(4) 478–490. DOI:<a href=\"https://doi.org/10.1007/s10637-017-0428-1\">10.1007/s10637-017-0428-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28138829/\">https://pubmed.ncbi.nlm.nih.gov/28138829</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX53;
